GLRX and metabolic syndrome: Intriguingly, AAV-Hep-Glrx treatment also significantly downregulated transcription of the gene Zbtb16 (zinc finger and BTB domain-containing 16), which encodes the transcription factor PLZF (promyelocytic leukemia zinc finger) that controls lymphocyte differentiation [45] and metabolic syndrome [46].